Relay kicks off public offering, seeking $300M on heels of robust ESMO data

Four days after joining the proverbial winner’s circle thanks to its bile duct cancer drug candidate, Relay Therapeutics is upping the ante and looking to up its coffers by a few hundred million for its next steps.